Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 5/10

vs
industry
vs
history
Cash to Debt 1.96
CADX's Cash to Debt is ranked higher than
61% of the 896 Companies
in the Global Biotechnology industry.

( Industry Median: 171.30 vs. CADX: 1.96 )
CADX' s 10-Year Cash to Debt Range
Min: 1.86   Max: No Debt
Current: 1.96

Equity to Asset 0.38
CADX's Equity to Asset is ranked higher than
55% of the 759 Companies
in the Global Biotechnology industry.

( Industry Median: 0.67 vs. CADX: 0.38 )
CADX' s 10-Year Equity to Asset Range
Min: 0.38   Max: 0.73
Current: 0.38

0.38
0.73
F-Score: 5
Z-Score: 6.84
M-Score: -2.31
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 4/10

vs
industry
vs
history
EBITDA Growth (%) -41.10
CADX's EBITDA Growth (%) is ranked higher than
55% of the 597 Companies
in the Global Biotechnology industry.

( Industry Median: -10.30 vs. CADX: -41.10 )
CADX' s 10-Year EBITDA Growth (%) Range
Min: -55.6   Max: 33.4
Current: -41.1

-55.6
33.4
EPS Growth (%) -36.40
CADX's EPS Growth (%) is ranked higher than
58% of the 617 Companies
in the Global Biotechnology industry.

( Industry Median: -12.80 vs. CADX: -36.40 )
CADX' s 10-Year EPS Growth (%) Range
Min: -54.8   Max: 0.7
Current: -36.4

-54.8
0.7
» CADX's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q1 2013

CADX Guru Trades in Q1 2013

Steven Cohen Sold Out
» More
Q2 2013

CADX Guru Trades in Q2 2013

Steven Cohen 16,477 sh (New)
» More
Q3 2013

CADX Guru Trades in Q3 2013

Paul Tudor Jones 30,700 sh (New)
Steven Cohen 6,100 sh (-62.98%)
» More
Q4 2013

CADX Guru Trades in Q4 2013

Jim Simons 54,300 sh (New)
Caxton Associates 75,000 sh (New)
Steven Cohen 17,842 sh (+192.49%)
Paul Tudor Jones 16,706 sh (-45.58%)
» More
» Details

Insider Trades

Latest Guru Trades with CADX



No Insider Trades Found!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 34.10
CADX's P/B is ranked lower than
76% of the 791 Companies
in the Global Biotechnology industry.

( Industry Median: 4.46 vs. CADX: 34.10 )
CADX' s 10-Year P/B Range
Min: 2.34   Max: 34.17
Current: 34.1

2.34
34.17
P/S 10.59
CADX's P/S is ranked higher than
50% of the 771 Companies
in the Global Biotechnology industry.

( Industry Median: 10.27 vs. CADX: 10.59 )
CADX' s 10-Year P/S Range
Min: 4.46   Max: 965
Current: 10.59

4.46
965

Valuation & Return

vs
industry
vs
history
Price/Net Cash 699.00
CADX's Price/Net Cash is ranked lower than
96% of the 477 Companies
in the Global Biotechnology industry.

( Industry Median: 9.30 vs. CADX: 699.00 )
CADX' s 10-Year Price/Net Cash Range
Min: 4.07   Max: 452.5
Current: 699

4.07
452.5
Price/Net Current Asset Value 93.20
CADX's Price/Net Current Asset Value is ranked lower than
91% of the 525 Companies
in the Global Biotechnology industry.

( Industry Median: 9.60 vs. CADX: 93.20 )
CADX' s 10-Year Price/Net Current Asset Value Range
Min: 3.95   Max: 60.33
Current: 93.2

3.95
60.33
Price/Tangible Book 49.90
CADX's Price/Tangible Book is ranked lower than
90% of the 736 Companies
in the Global Biotechnology industry.

( Industry Median: 6.00 vs. CADX: 49.90 )
CADX' s 10-Year Price/Tangible Book Range
Min: 3.19   Max: 32.32
Current: 49.9

3.19
32.32
Price/Median PS Value 1.10
CADX's Price/Median PS Value is ranked higher than
60% of the 725 Companies
in the Global Biotechnology industry.

( Industry Median: 1.10 vs. CADX: 1.10 )
CADX' s 10-Year Price/Median PS Value Range
Min: 0.61   Max: 102
Current: 1.1

0.61
102
Forward Rate of Return (Yacktman) -25.51
CADX's Forward Rate of Return (Yacktman) is ranked higher than
68% of the 669 Companies
in the Global Biotechnology industry.

( Industry Median: -9.87 vs. CADX: -25.51 )
CADX' s 10-Year Forward Rate of Return (Yacktman) Range
Min: -5.2   Max: 12.5
Current: -25.51

-5.2
12.5

Business Description

Industry: Biotechnology » Biotechnology
Compare:NVO, AMGN, GILD, BIIB, CELG » details
Traded in other countries:QEW.Germany
Cadence Pharmaceuticals, Inc. is a biopharmaceutical company focused on in-licensing, developing and commercializing product candidates mainly for use in the hospital setting. The Company's main activities are conducting research and development activities as well as conducting clinical trials. The company has in-licensed rights to products: Acetavance, an intravenous formulation of acetaminophen, and Omigard, an omiganan pentahydrochloride 1% aqueous gel. It in-licensed the exclusive United States, or U.S., and Canadian rights to Acetavance from Bristol-Myers Squibb Company, or BMS, which markets this product candidate in Europe and other markets for the treatment of acute pain and fever under the brand name Perfalgan. The Company is developing Acetavance, a proprietary intravenous formulation of acetaminophen, for the U.S. market for the treatment of acute pain and fever in adults and children. In its oral form, acetaminophen is the most widely used drug for the treatment of pain and fever in the U.S. The Company's licensor, BMS, currently markets this proprietary intravenous formulation of acetaminophen for the treatment of acute pain and fever in Europe and several other markets outside the U.S, where it is known as paracetamol and is marketed under the brand name Perfalgan.

Personalized Checklist








Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

Add Notes, Comments or Ask Questions

User Comments

No comment yet

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK
Hide